Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort

Hepatology

Volumn 34, Issue 2, 2001, Pages 411-416

  Yao, Francis Y ^a   Terrault, Norah A ^a   Freise, Chris ^a   Maslow, Lin ^a   Bass, Nathan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD PUGH TURCOTTE SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; VIRUS REPLICATION;

EID: 0034927065     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.26512     Document Type: Article

References (29)

1. A one-year trial of lamivudine for chronic hepatitis B
2. Lamivudine as initial treatment for chronic hepatitis B in the United States
3. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
4. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
5. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
6. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
7. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
8. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
9. Transection of the oesophagus for bleeding oesophageal varices
10. Hepatic encephalopathy
11. Summary of guidelines on organ allocation and patient listing for liver transplantation
12. Is lamivudine beneficial in HBsAg+ patients awaiting liver transplantation? Experience in 182 North American patients
13. Increased waiting time for liver transplantation results in higher mortality
14. Mitochondrial toxicity: New adverse drug effects
15. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B
16. Emergence and takeover of YMDD motif hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
17. Hepatitis B virus mutants associated with 3TC and famciclovir are replication defective
18. Lamivudine resistance in immunocompetent chronic hepatitis B
19. The role of pre-transplant treatment with lamivudine in hepatitis B surface antigen positive patients undergoing liver transplantation
20. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
21. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
22. Post liver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long term follow up
23. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
24. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
25. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
26. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
27. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: For whom and when?
28. Antiviral chemotherapy for the treatment of hepatitis B virus infections
29. Combination chemotherapy for hepatitis B virus: The final solution?